cat
expos
felin
infecti
periton
viru
fipv
felin
enter
coronaviru
fecv
differenti
serolog
analysi
three
synthet
peptid
e
coli
recombin
fusion
protein
gener
fipv
spike
gene
sequenc
produc
coronaviru
posit
cat
sera
react
peptid
aa
nonreact
aa
peptid
demonstr
elisa
amino
acid
sequenc
express
galk
fusion
protein
e
coli
test
coronaviru
posit
cat
sera
western
blot
analysi
sera
cat
expos
fipv
typeii
strain
exhibit
sign
fip
recogn
fusion
protein
sera
fecv
expos
cat
recogn
fusion
protein
western
blot
analysi
antigalk
monoclon
antibodi
mab
obtain
mous
ascit
fluid
smithklin
beecham
depart
molecular
genet
antigalk
mab
semi
felin
infecti
periton
viru
fipv
caus
agent
felin
infecti
periton
fip
complex
fatal
diseas
cat
contrast
felin
enter
coronaviru
fecv
caus
enter
virus
member
coronaviru
famili
group
envelop
virus
contain
singlestrand
posit
sens
messeng
rna
felin
enter
coronaviru
fipv
distinguish
base
virul
separ
antigen
serolog
base
cat
challeng
studi
fipv
fecv
isol
design
term
increas
virul
follow
fecv
strain
fipv
fipv
fipv
sever
current
vitro
assay
enzym
link
immunoabsob
assay
elisa
indirect
fluoresc
antibodi
assay
ifa
identifi
coronaviru
seroposit
cat
due
high
degre
cross
reaction
fecv
fipv
test
use
distinguish
one
infect
addit
littl
correl
elisa
viru
neutral
titer
clinic
manifest
diseas
three
fipv
structur
protein
glycoprotein
like
suitabl
target
diagnost
purpos
protein
coronaviru
known
bind
hostcel
receptor
glycoprotein
induc
cell
fusion
protein
induc
strong
antibodi
respons
well
respons
associ
fipv
diseas
enhanc
case
coronavirus
transmiss
gastroenter
viru
tgev
infecti
bronchiti
viru
ibv
mous
hepat
viru
mhv
protein
appear
major
induc
protect
immun
n
protein
fipv
fecv
contain
groupspecif
epitop
wherea
protein
contain
typespecif
epitop
although
aa
sequenc
protein
fecv
isol
avail
heterogen
among
protein
sever
coronavirus
locat
particular
region
protein
aa
sequenc
heterolog
fipv
strain
tgev
approxim
aa
among
residu
heterogen
among
coronavirus
includ
ibv
h
v
locat
region
like
heterogen
fipv
fecv
area
purpos
studi
investig
predict
heterogen
fipv
fecv
could
exploit
gener
reagent
could
help
differenti
virul
avirul
coronavirus
develop
test
would
correl
clinic
diseas
three
peptid
correspond
fipv
wsu
strain
spike
aa
sequenc
synthes
palkoxybenzyl
alcohol
resin
complet
peptid
cleav
resin
acid
condit
purifi
revers
phase
hplc
purifi
peptid
conjug
via
glutaraldehyd
ovalbumin
ova
ratio
purifi
peptid
also
coniug
via
sulfomb
human
serum
albumin
hsa
ratio
three
ova
conjug
inject
three
rabbit
design
ia
lb
lc
rabbit
receiv
prime
dose
equival
gg
peptid
complet
freund
adjuv
intramuscularli
im
four
week
post
immun
rabbit
receiv
booster
dose
equival
gg
peptid
incomplet
freund
adjuv
im
ten
day
immun
rabbit
bled
reactiv
rabbit
antisera
whole
viru
protein
test
western
blot
analysi
elisa
rabbit
antisera
shown
peptid
specif
elisa
data
shown
clone
procedur
similar
describ
maniati
bacteri
express
vector
develop
dr
c
debouck
skf
lab
swedeland
pa
design
regul
express
clone
gene
galk
fusion
protein
specif
strain
e
coli
express
foreign
gene
control
lambda
bacteriophag
pl
promot
transcript
gatk
inhibit
presenc
lambda
cl
repressor
repressor
remov
express
induc
uniqu
restrict
site
introduc
first
aa
bacteri
enzym
galactokinas
code
sequenc
express
induc
cultur
upon
heat
repressor
thermolabil
templat
pcr
reaction
doubl
strand
cdna
variant
fipv
prepar
rna
extract
infect
cell
pcr
standard
specifi
cetu
corpor
follow
incub
perkin
elmer
cetu
thermocycl
cycl
complet
pcr
reaction
product
analyz
agaros
gel
confirm
amplif
predict
dna
fragment
dna
pcr
reaction
mixtur
digest
xmai
stui
digest
dna
extract
phenol
follow
phenolchloroform
extract
ethanol
precipit
xmaistui
digest
dna
incub
ligat
mix
contain
vector
dna
digest
xmalstui
dephosphoryl
compet
cell
transform
insertbear
clone
identifi
restrict
digest
small
scale
dna
prepar
dna
confirm
clone
use
transform
heatinduc
strain
e
coll
sequenc
analysi
gene
encod
recombin
spike
fusion
protein
confirm
predict
sequenc
clone
fusion
protein
contain
aa
e
coil
galk
protein
fuse
aa
fipv
spike
protein
clone
cell
pellet
treat
lysozymeedta
final
concentr
ram
room
temperatur
rt
h
mixtur
sonic
rain
ice
inactiv
addit
thimeros
ten
ml
inactiv
extract
centrifug
x
g
min
pellet
resuspend
vortex
rain
ml
buffer
mm
tri
hct
ph
mm
edta
mm
dtt
vv
glycerol
buffer
also
contain
wv
sodium
deoxychol
acid
vv
triton
extract
centrifug
x
g
pellet
resuspend
buffer
contain
triton
potassium
chlorid
extract
centrifug
pellet
resuspend
ml
buffer
contain
urea
extract
centrifug
supernat
dilut
addit
pb
ph
materi
appli
antigalk
affin
column
purifi
twice
precipit
satur
ammonium
sulfat
respect
ten
milligram
antigalk
mab
immobil
pierc
immunopur
tm
agab
column
column
equilibr
mm
pb
ph
column
receiv
wash
urea
equilibr
pb
protein
elut
ph
five
ml
fraction
collect
neutral
trishct
ph
second
third
fraction
contain
protein
shown
direct
elisa
use
antigalk
mab
sdspage
perform
slab
gel
reduc
condit
separ
gel
stack
gel
contain
polyacrylamid
respect
sampl
buffer
contain
vv
betamercaptoethanol
affinitypurifi
recombin
spike
fusion
protein
concentr
approxim
btggel
mix
sampl
buffer
boil
rain
electrophoresi
perform
rt
h
constant
current
affin
purifi
recombin
spike
fusion
protein
separ
sdspage
transfer
nitrocellulos
sheet
txm
pore
size
transfer
carri
electrophoret
method
towbin
et
al
nitrocellulos
sheet
block
buffer
b
tri
sodium
chlorid
ph
wv
nonfat
dri
milk
incub
overnight
rt
nitrocellulos
strip
cut
place
individu
chamber
incub
h
rt
cat
serum
dilut
buffer
b
strip
contain
approxim
gg
fusion
protein
aa
strip
wash
buffer
c
buffer
b
vv
triton
wash
twice
buffer
b
wash
complet
strip
incub
rt
hour
horseradish
peroxidaseconjug
goat
antibodi
cat
mous
igg
kirkegaard
perri
laboratori
gaithersburg
md
dilut
buffer
b
strip
wash
incub
bcipnbt
phosphatas
substrat
system
kirkegaard
perri
presenc
antibodi
coronaviru
cat
sera
determin
direct
antigen
bind
elisa
viru
neutral
fipv
specif
pathogenfre
spf
cat
month
age
free
serum
anticoronaviru
antibodi
obtain
liberti
lab
liberti
n
j
usa
cat
serv
nonvaccin
control
other
vaccin
twice
intranas
day
primucellfip
temperatur
sensit
modifi
five
vaccin
smithklin
beecham
anim
health
west
chester
pa
virul
fipv
strain
titrat
per
ml
one
ml
given
per
cat
oral
day
post
second
vaccin
addit
cat
anticoronaviru
elisa
titer
neg
fipv
neutral
titer
receiv
mason
citi
smithklin
beecham
anim
health
sourc
cat
part
coloni
void
fipv
clinic
symptom
naiv
spf
cat
receiv
three
exposur
fecv
strain
three
week
interv
cat
challeng
fipv
group
base
clinic
evalu
use
clinic
score
protocol
describ
previous
symptom
febril
respons
lymphopenia
leukopenia
icteru
decreas
pack
cell
volum
evalu
total
clinic
score
sum
clinic
score
durat
studi
cat
total
clinic
score
less
design
nonsymptomat
ns
cat
total
clinic
score
design
symptomat
cat
routin
bled
prevaccin
post
first
vaccin
post
second
vaccin
two
four
six
eight
week
postchalleng
aa
sequenc
fipv
spike
protein
survey
potenti
antigen
site
use
number
criteria
hydrophil
profil
surfac
probabl
chain
flexibl
antigen
index
factor
along
secondari
structur
predict
analyz
use
univers
wisconsin
genet
group
program
graphic
represent
factor
appear
fig
peptid
homolog
high
antigen
index
residu
publish
fipv
spike
protein
synthes
two
n
termin
region
residu
select
base
upon
heterogen
fipv
tgev
region
ell
peptid
chosen
region
homolog
sequenc
synthet
spike
peptid
use
solid
phase
antigen
elisa
attempt
differenti
fipv
fecv
antibodi
expos
cat
sera
gener
polyclon
rabbit
antipeptid
sera
cat
sera
test
abil
recogn
three
synthet
peptid
conjug
naiv
spf
cat
sera
neg
antibodi
specif
three
hsaconjug
peptid
aa
elisa
sera
cat
expos
either
fipv
fecv
found
react
conjug
tabl
aa
sequenc
peptid
conjug
recogn
antibodi
cat
locat
within
spike
ntermin
region
residu
demonstr
heterogen
fipv
tgev
sinc
synthet
peptid
may
short
immun
recognit
longer
peptid
contain
two
region
produc
recombin
dna
technolog
recombin
e
coli
fusion
protein
design
contain
larger
spike
protein
sequenc
use
investig
serolog
crossreact
region
contain
residu
galk
residu
repres
aa
ts
fipv
spike
protein
exact
homolog
fipv
region
affinitypurifi
fusion
protein
prepar
approxim
seventi
western
blot
analysi
k
fusion
protein
clearli
identifi
reactiv
galk
portion
antigalk
mab
f
p
v
spike
protein
portion
rabbit
antisera
peptid
aa
aa
fig
initi
western
blot
analysi
sera
eight
cat
demonstr
postchalleng
sera
cat
surviv
fipv
challeng
contain
antibodi
recogn
fusion
protein
contrast
antibodi
postchalleng
sera
cat
surviv
f
p
v
challeng
non
reactiv
fusion
protein
fig
reactiv
sera
nonsurviv
cat
independ
challeng
strain
f
four
nonsurviv
cat
two
challeng
f
p
v
fig
two
strain
f
fig
solid
phase
antigen
use
elisa
partial
purifi
fipv
antigen
use
western
blot
analysi
affin
purifi
ar
fusion
protein
gg
per
tane
fig
serolog
respons
fusion
protein
symptomat
cat
expos
virul
typeii
fipv
western
blot
analysi
analysi
antibodi
reactiv
perform
take
consider
diseas
sever
sera
addit
cat
challeng
either
fipv
wsu
fipv
group
symptomat
nonsymtomat
base
clinic
score
system
describ
earlier
sera
two
group
cat
test
abil
recogn
spike
fusion
protein
western
blot
analysi
shown
tabl
antibodi
respons
correl
diseas
state
cat
eightytwo
percent
symptomat
cat
contain
antibodi
react
contrast
eightysix
percent
nonsymptomat
cat
neg
spike
fusion
protein
symptomat
cat
neg
die
two
four
week
post
challeng
therefor
two
four
week
post
challeng
sera
avail
test
figur
show
result
western
blot
analysi
sera
symptomat
cat
test
spike
fusion
protein
figur
show
major
neg
reactiv
symptomat
cat
occur
two
week
post
challeng
sera
wherea
six
eight
week
post
therefor
clear
even
higher
percent
symptomat
cat
could
identifi
sera
collect
sever
time
point
test
sera
test
western
blot
cat
challeng
fipv
demonstr
anticoronaviru
antibodi
analyz
elisa
viru
neutral
analysi
shown
fig
fig
respect
demonstr
cat
respond
serolog
fipv
post
challeng
viru
neutral
titer
show
better
correl
elisa
titer
reactiv
western
blot
analysi
serum
antibodi
cat
expos
three
time
fecv
strain
react
spike
fusion
protein
western
blot
analysi
howev
serum
sixteen
cat
show
anticoronaviru
antibodi
titer
elisa
see
tabl
solid
phase
antigen
use
elisa
partial
purifi
fipv
antigen
use
western
blot
analysi
affin
purifi
ar
fusion
protein
gg
per
lane
sera
either
symptomat
nonsymptomat
cat
challeng
fipv
strain
recogn
serum
sixteen
cat
test
show
high
anticoronaviru
antibodi
titer
elisa
tabl
thu
fusion
protein
use
identifi
cat
expos
fipv
strain
felin
infecti
periton
viru
fecv
natur
pathogen
cat
caus
strikingli
differ
diseas
yet
share
extens
crossreact
present
time
possibl
differenti
one
infect
serolog
mean
howev
gene
virus
like
target
variabl
gene
fipv
sequenc
shown
compar
relat
coronaviru
tgev
heterogen
confin
ntermin
aa
felin
enter
coronaviru
fipv
may
also
differ
ntermini
time
studi
fecv
sequenc
avail
synthet
peptid
e
coli
recombin
use
defin
region
possibl
heterogen
within
fipv
ts
spike
protein
ntermin
aa
fragment
ts
fipv
express
e
coli
recombin
clone
may
contain
epitop
uniqu
fipv
strain
present
fecv
three
peptid
region
protein
fipv
select
base
antigen
profil
locat
within
spike
protein
two
ntermin
peptid
design
look
region
heterogen
ctermin
peptid
expect
recogn
antibodi
cat
infect
coronaviru
peptid
excel
antigen
profil
base
comput
analysi
primari
aa
sequenc
predict
region
surfaceexpos
approach
use
talbot
et
al
produc
synthet
peptid
homolog
residu
murin
hepat
viru
mhv
strain
jhm
mhv
spike
peptid
conjug
keyhol
limpet
hemocyanin
found
elicit
high
level
neutral
antibodi
protect
mice
lethal
mhv
challeng
three
group
rabbit
immun
ova
conjug
either
aa
aa
aa
homolog
protein
fipv
strain
sera
rabbit
contain
antibodi
react
viral
antigen
fipv
strain
elisa
western
blot
analysi
data
shown
although
antipeptid
antibodi
rais
rabbit
recogn
nativ
fipv
spike
protein
least
one
peptid
recogn
antisera
cat
expos
fipv
synthet
peptid
conjug
contain
either
ntermin
ctermin
fipv
strain
spike
protein
aa
also
screen
sera
cat
expos
fipv
fecv
elisa
ctermin
synthet
peptid
recogn
cat
sera
either
fipv
fecv
expos
cat
therefor
antibodi
peptid
could
differenti
fipv
fecv
ctermin
peptid
contain
residu
larger
ntermin
peptid
increas
size
may
allow
ctermin
peptid
fold
therefor
mimic
conform
epitop
found
nativ
fipv
fecv
spike
protein
howev
investig
identifi
linear
neutral
epitop
mhv
strain
aa
mhv
strain
jhm
aa
similar
locat
residu
sequenc
aa
main
object
studi
differenti
cat
expos
fipv
fecv
howev
describ
previous
two
synthet
peptid
base
ntermin
spike
protein
sequenc
recogn
cat
sera
antibodi
evalu
two
ntermin
peptid
may
repres
nonimmunodomin
region
portion
discontinu
epitop
therefor
target
natur
fipv
fecv
induc
humor
respons
therefor
larger
spike
protein
fragment
produc
includ
sequenc
two
smaller
peptid
recombin
e
coii
clone
express
fusion
protein
contain
aa
host
galactokinas
protein
ts
fipv
spike
protein
homolog
residu
ts
fipv
fusion
protein
express
e
coli
form
aggreg
structur
inclus
bodi
strong
denatur
condit
requir
inclus
bodi
solubil
prior
affin
purif
addit
reduc
western
blot
analysi
therefor
recombin
e
coli
antigen
suitabl
identifi
categori
epitop
detect
use
synthet
peptid
name
linear
sequenti
epitop
western
blot
analysi
coronaviru
posit
cat
sera
show
sera
cat
challeng
fipv
react
fusion
protein
furthermor
seventytwo
cat
challeng
either
fipv
could
separ
two
group
base
upon
manifest
fipv
clinic
symptom
fifti
symptomat
cat
eightytwo
percent
posit
eighteen
percent
neg
recombin
fusion
protein
twentytwo
nonsymptomat
cat
eightysix
percent
nonreact
fourteen
percent
recogn
aa
sequenc
symptomat
cat
may
difficulti
clear
viru
compar
nonsymptomat
cat
therefor
extens
viral
replic
may
occur
symptomat
cat
give
immun
system
opportun
produc
antibodi
epitop
seen
nonsymptomat
anim
thu
differenti
diseas
healthi
cat
may
possibl
use
ar
fusion
protein
western
blot
analysi
order
demonstr
reactiv
fusion
protein
function
antibodi
concentr
post
challeng
sera
titrat
elisa
viru
neutral
analysi
use
fipv
although
cat
sera
high
elisa
titer
usual
show
posit
reactiv
western
blot
analysi
except
shown
fig
therefor
littl
correl
could
establish
reactiv
aa
peptid
elisa
titer
howev
correl
establish
reactiv
cat
serum
antibodi
fusion
protein
western
blot
analysi
viru
neutral
titer
fig
protein
concentr
fusion
protein
constant
western
blot
analys
cat
sera
dilut
thirti
fold
howev
total
concentr
antispik
protein
specif
antibodi
probabl
vari
among
cat
sera
test
previous
describ
elisa
result
indic
reactiv
western
blot
function
high
antibodi
titer
alon
support
theori
antibodi
respons
fusion
protein
relat
diseas
state
cat
cat
expos
fecv
recogn
recombin
fusion
protein
observ
encourag
suggest
might
possibl
differenti
cat
expos
virul
fipv
strain
avirul
fecv
fecv
gene
recent
sequenc
compar
publish
gene
interest
result
shown
term
aa
homolog
show
greater
aa
homolog
although
share
greater
aa
homolog
fecv
aa
differ
respect
within
ntermin
half
protein
addit
high
aa
diverg
observ
aa
aa
differ
fipv
fecv
abil
fusion
protein
differenti
fipv
fecv
expos
cat
may
part
due
diverg
observ
region
aa
howev
sera
cat
expos
virul
fipv
strain
tn
detect
aa
fusion
protein
tn
strain
fipv
classifi
virul
typei
viru
wherea
virul
typeii
virus
fecv
avirul
typeii
viru
base
lack
reactiv
inabl
sera
cat
expos
tn
cross
neutral
would
appear
type
fipv
strain
may
contain
region
consider
heterogen
therefor
diagnost
assay
use
recombin
fusion
protein
antigen
substrat
differenti
cat
expos
virul
strain
fipv
expos
avirul
strain
fipv
fecv
would
possibl
spike
protein
gene
sequenc
data
need
typei
fipv
name
strain
tn
inform
would
help
locat
possibl
conserv
region
uniqu
virul
strain
fipv
conclus
recombin
e
coli
fusion
protein
recogn
antibodi
cat
clinic
manifest
fip
exposur
virul
typeii
strain
fipv
contrast
antibodi
cat
expos
f
e
c
v
avirul
typeii
viru
react
western
blot
analysi
howev
sera
cat
infect
strain
n
fipv
irrespect
whether
cat
becam
sick
remain
healthi
recogn
fusion
protein
spike
gene
sequenc
virul
avirut
strain
f
p
v
need
identifi
region
contain
typespecif
epitop
furthermor
express
addit
recombin
spike
protein
fragment
explor
target
region
biolog
import
